Sigma-1 Receptor Agonist Compounds for Neuroprotective Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a strong need for the development of new sigma-1 receptor agonists to treat cognitive disorders related to psychiatric pathologies, neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, as well as genetic diseases associated with Mitochondria Associated Membranes (MAM) dysfunctions.
Innovation Solution
Development of compounds with specific formula (I) that act as sigma-1 receptor agonists, including various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups, optionally substituted with specific functional groups, for use in pharmaceutical compositions to treat disorders modulated by the sigma-1 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing sigma-1 receptor agonists are used to treat cognitive and neurodegenerative disorders, then therapeutic effects are achieved, but limitations in efficacy and specificity remain
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular structures of sigma-1 receptor agonists through varying substituents (R1-R6) at different positions of the core pharmacophore. This enables optimization of binding affinity, selectivity, and pharmacokinetic properties to enhance therapeutic efficacy while reducing limitations of existing agents
2Adaptability or versatility
If new sigma-1 receptor agonists are developed to expand treatment coverage, then versatility improves, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core pharmacophore structure and variable substituent groups (R1-R6). This modular approach allows systematic exploration of structure-activity relationships to expand treatment coverage while managing development complexity through organized molecular design
Solution Approach 2:
The patent applies universality by designing a core pharmacophore structure that maintains sigma-1 receptor binding capability while allowing diverse substituent variations. This enables a single molecular framework to serve multiple therapeutic indications across cognitive and neurodegenerative disorders, enhancing versatility without proportionally increasing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate sigma-1 receptors, providing therapeutic benefits for cognitive and neurodegenerative disorders by enhancing calcium exchange, inducing ER stress pathways, and promoting neuroprotection, thereby alleviating symptoms of Alzheimer's, Parkinson's, Huntington's disease, ALS, and multiple sclerosis.
Implementation Method 1
These compounds demonstrate affinity for sigma-1 receptors
Data Source
AI summary
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.